Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) (OCTP) said it has appointed Paul William Smalley as its new group finance director with effect from today, 17 October 2022.
Smalley succeeds Karen Lowe, who is leaving at the end of this month, the pharmaceutical company said in a statement.
Julie Pomeroy, OCTP’s non-executive chair, noted that Smalley brings with him “a number of years' strategic financial management experience from the life science and wider sectors, in both the UK and mainland Europe”.
Smalley joins the company from Panthera Biopartners Ltd, a clinical trials management company where he was the finance director and company secretary overseeing financial and treasury management, as well as assisting with mergers and acquisitions.
As a CIMA-qualified accountant, he has more than 25 years' UK and international financial experience including strategic management capabilities gained across a wide range of market sectors, with expertise extending to IT, HR and procurement, OCTP said.